Growth Hormone Therapy in the Pediatric Setting: Early Intervention and The Emergence of Long-Acting AgentsPremiere Date: Tuesday, January 25, 2022
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Saturday, February 25, 2023
|Kevin C.J. Yuen, MD, FRCP (UK), FACE (Moderator)
Medical Director of Barrow Pituitary Center
Barrow Neurological Institute
Professor of Medicine
University of Arizona College of Medicine and Creighton School of Medicine
|Bradley S. Miller, MD, PhD
Professor of Pediatrics
Director, Division of Pediatric Endocrinology
University of Minnesota
Masonic Children's Hospital
Although sometimes dismissed as a social or cosmetic condition, growth hormone deficiency (GHD) is a serious medical condition with significant risks for long-term health problems. The use of growth hormone therapy (GHT) is an effective intervention, but good adherence to daily injections is often a challenging prospect for children and those transitioning from pediatric to adult care. Shared decision-making with patients and families, and the use of novel, long-acting GHT formulations, are important tools for potentially improving adherence and clinical outcomes.
In this CMEOCast podcast, renowned experts in growth disorders present two patient cases to illustrate real-world challenges and contemporary GHD management. Clinical trial results for new and emerging long-acting growth hormone therapies are also reviewed to optimize treatment decisions in patients with GHD.
At the end of this CE activity, participants should be able to:
- Implement evidence-based guidelines for the diagnosis of GHD in pediatric patients.
- Interpret safety and efficacy data for once-daily and once-weekly GH therapies (GHTs).
- Apply evidence on the relationship between GHT adherence and outcomes to patient counseling practices and treatment decisions for pediatric patients.
Supported by an educational grant from Novo Nordisk Inc.
Pediatric endocrinologists, adult endocrinologists, pediatricians, pediatric endocrine nurses, and pediatric nurses
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Yuen reports the following financial relationships:
Advisory Board: Ascendis Pharma Group; Chiasma, Inc.; Corcept; Ipsen Pharma; Novo Nordisk; Rani Therapeutics; and Recordati
Research Support: (All paid to Barrow Neurological Institute) Ascendis Pharma Group; Corcept; Crinetics Pharmaceuticals, Inc.; Millendo Therapeutics; and Novartis
Dr. Miller reports the following financial relationships:
Consultant: AbbVie Inc.; Ascendis Pharma Group; BioMarin; EMD Serono; Novo Nordisk; Orchard Therapeutics; Pfizer Inc.; Tolmar Pharmaceuticals, Inc.; and Vertice Pharma
Research Support: Alexion Pharmaceuticals, Inc.; AbbVie Inc.; Amgen Inc.; Ascendis Pharma Group; Lumos Pharma; Novo Nordisk; OPKO Health, Inc.; and Pfizer Inc.
The following peer reviewer and CME Outfitters staff have no financial relationships to disclose:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).